All Resources

Access to Medicine • June 28, 2022

Search for Specific Brand Name Drug Negotiations Status with the pCPA

Learn more|View

Access to Medicine • June 28, 2022

pCPA overview of the Negotiation Process

Learn more about the negotiation process from the pCPA….

Learn more|View

November 25, 2021

Innovative Agreements Framework Industry Oct 2021

Learn more|View

Access to Medicine • October 01, 2021

Innovative Agreements Framework

…describes innovative agreements being used in jurisdictions outside Canada. We prepared it to guide discussions with the pCPA Governing Council on the merits of jointly developing an innovative agreements framework….

Learn more|View

Drugs for Rare Diseases (DRD) • March 26, 2021

Towards a Value-based and Pan-Canadian Rare Disease Strategy

Learn more|View

Access to Medicine • August 20, 2020

IMC and BTC joint response to CADTH’s transparency consultation

Learn more|View

January 30, 2020

2019 Annual Report

Learn more|View

September 27, 2019

Note for guidance on patient support programs and medical practice activities

Learn more|View

June 30, 2019

Cost Drivers Analysis of Private Drug Plans in Canada 2016-2018

Learn more|View

Access to Medicine • April 28, 2019

pCPA Brand Practice Guidelines

Learn more about pCPA Brand Practice Guidelines….

Learn more|View

March 29, 2019

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans (March 2019)

Learn more|View

February 18, 2019

Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications (February 2019)

Learn more|View